Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing

Valentina Zampiga, Rita Danesi, Gianluca Tedaldi, Michela Tebaldi, Ilaria Cangini, Francesca Pirini, Cristina Pittureri, Elena Amaducci, Luciano Guidi, Marina Faedi, Dino Amadori, Fabio Falcini, Daniele Calistri

Research output: Contribution to journalArticle

Abstract

Li-Fraumeni syndrome (LFS) is an autosomal dominant disorder occurring at a young age that predisposes individuals to multiple forms of cancer and to a heterogeneous spectrum of malignancies. We describe the clinical history of a patient who had 5 primary malignant cancers and a familiar history consistent with LFS. We analyzed the genomic DNA of the proband and her relatives by next-generation sequencing (NGS) technology using an enrichment protocol for the simultaneous sequencing of 94 genes involved in hereditary cancers. Genetic analysis of the proband revealed a TP53 germline mutation in exon 5 determining a nucleotide alteration at codon 175 (R175H), a hot spot mutation site related to LFS and a reported pathogenic mutation. The proband daughter's and brother's DNA did not carry the TP53 mutation but they had some rare variants in common with the proband, in addition to other variants with a still unclear role. In conclusion, we identified a TP53 mutation in a patient with multiple primary tumors and a family history characterized by a severe susceptibility to cancer. The genetic analysis by targeted NGS led to the identification of the genetic background and to the exclusion of a cancer risk for the family members. Targeted NGS represents an efficient approach for the identification of mutations in families with a heterogeneous phenotype.

Original languageEnglish
Pages (from-to)e461-e465
JournalInternational Journal of Biological Markers
Volume31
Issue number4
DOIs
Publication statusPublished - Dec 23 2016

Fingerprint

Li-Fraumeni Syndrome
Germ-Line Mutation
Tumors
DNA
Mutation
Exons
Neoplasms
Nucleotides
Genes
History
Nuclear Family
Codon
Siblings
Technology
Phenotype

Keywords

  • Journal Article

Cite this

Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing. / Zampiga, Valentina; Danesi, Rita; Tedaldi, Gianluca; Tebaldi, Michela; Cangini, Ilaria; Pirini, Francesca; Pittureri, Cristina; Amaducci, Elena; Guidi, Luciano; Faedi, Marina; Amadori, Dino; Falcini, Fabio; Calistri, Daniele.

In: International Journal of Biological Markers, Vol. 31, No. 4, 23.12.2016, p. e461-e465.

Research output: Contribution to journalArticle

Zampiga, Valentina ; Danesi, Rita ; Tedaldi, Gianluca ; Tebaldi, Michela ; Cangini, Ilaria ; Pirini, Francesca ; Pittureri, Cristina ; Amaducci, Elena ; Guidi, Luciano ; Faedi, Marina ; Amadori, Dino ; Falcini, Fabio ; Calistri, Daniele. / Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing. In: International Journal of Biological Markers. 2016 ; Vol. 31, No. 4. pp. e461-e465.
@article{b91d6169f4624dfcbe98117e83270de2,
title = "Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing",
abstract = "Li-Fraumeni syndrome (LFS) is an autosomal dominant disorder occurring at a young age that predisposes individuals to multiple forms of cancer and to a heterogeneous spectrum of malignancies. We describe the clinical history of a patient who had 5 primary malignant cancers and a familiar history consistent with LFS. We analyzed the genomic DNA of the proband and her relatives by next-generation sequencing (NGS) technology using an enrichment protocol for the simultaneous sequencing of 94 genes involved in hereditary cancers. Genetic analysis of the proband revealed a TP53 germline mutation in exon 5 determining a nucleotide alteration at codon 175 (R175H), a hot spot mutation site related to LFS and a reported pathogenic mutation. The proband daughter's and brother's DNA did not carry the TP53 mutation but they had some rare variants in common with the proband, in addition to other variants with a still unclear role. In conclusion, we identified a TP53 mutation in a patient with multiple primary tumors and a family history characterized by a severe susceptibility to cancer. The genetic analysis by targeted NGS led to the identification of the genetic background and to the exclusion of a cancer risk for the family members. Targeted NGS represents an efficient approach for the identification of mutations in families with a heterogeneous phenotype.",
keywords = "Journal Article",
author = "Valentina Zampiga and Rita Danesi and Gianluca Tedaldi and Michela Tebaldi and Ilaria Cangini and Francesca Pirini and Cristina Pittureri and Elena Amaducci and Luciano Guidi and Marina Faedi and Dino Amadori and Fabio Falcini and Daniele Calistri",
year = "2016",
month = "12",
day = "23",
doi = "10.5301/jbm.5000227",
language = "English",
volume = "31",
pages = "e461--e465",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing

AU - Zampiga, Valentina

AU - Danesi, Rita

AU - Tedaldi, Gianluca

AU - Tebaldi, Michela

AU - Cangini, Ilaria

AU - Pirini, Francesca

AU - Pittureri, Cristina

AU - Amaducci, Elena

AU - Guidi, Luciano

AU - Faedi, Marina

AU - Amadori, Dino

AU - Falcini, Fabio

AU - Calistri, Daniele

PY - 2016/12/23

Y1 - 2016/12/23

N2 - Li-Fraumeni syndrome (LFS) is an autosomal dominant disorder occurring at a young age that predisposes individuals to multiple forms of cancer and to a heterogeneous spectrum of malignancies. We describe the clinical history of a patient who had 5 primary malignant cancers and a familiar history consistent with LFS. We analyzed the genomic DNA of the proband and her relatives by next-generation sequencing (NGS) technology using an enrichment protocol for the simultaneous sequencing of 94 genes involved in hereditary cancers. Genetic analysis of the proband revealed a TP53 germline mutation in exon 5 determining a nucleotide alteration at codon 175 (R175H), a hot spot mutation site related to LFS and a reported pathogenic mutation. The proband daughter's and brother's DNA did not carry the TP53 mutation but they had some rare variants in common with the proband, in addition to other variants with a still unclear role. In conclusion, we identified a TP53 mutation in a patient with multiple primary tumors and a family history characterized by a severe susceptibility to cancer. The genetic analysis by targeted NGS led to the identification of the genetic background and to the exclusion of a cancer risk for the family members. Targeted NGS represents an efficient approach for the identification of mutations in families with a heterogeneous phenotype.

AB - Li-Fraumeni syndrome (LFS) is an autosomal dominant disorder occurring at a young age that predisposes individuals to multiple forms of cancer and to a heterogeneous spectrum of malignancies. We describe the clinical history of a patient who had 5 primary malignant cancers and a familiar history consistent with LFS. We analyzed the genomic DNA of the proband and her relatives by next-generation sequencing (NGS) technology using an enrichment protocol for the simultaneous sequencing of 94 genes involved in hereditary cancers. Genetic analysis of the proband revealed a TP53 germline mutation in exon 5 determining a nucleotide alteration at codon 175 (R175H), a hot spot mutation site related to LFS and a reported pathogenic mutation. The proband daughter's and brother's DNA did not carry the TP53 mutation but they had some rare variants in common with the proband, in addition to other variants with a still unclear role. In conclusion, we identified a TP53 mutation in a patient with multiple primary tumors and a family history characterized by a severe susceptibility to cancer. The genetic analysis by targeted NGS led to the identification of the genetic background and to the exclusion of a cancer risk for the family members. Targeted NGS represents an efficient approach for the identification of mutations in families with a heterogeneous phenotype.

KW - Journal Article

U2 - 10.5301/jbm.5000227

DO - 10.5301/jbm.5000227

M3 - Article

C2 - 27516001

VL - 31

SP - e461-e465

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -